{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:21Z","timestamp":1794047481273,"version":"4.8.0"},"reference-count":14,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2024.285043","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T08:24:50Z","timestamp":1717057490000},"page":"3379-3382","source":"Crossref","is-referenced-by-count":8,"title":["The phase III DUO trial of PI3K inhibitor duvelisib &lt;i&gt;versus&lt;\/i&gt; ofatumumab in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: final analysis including overall survival"],"prefix":"10.3324","volume":"109","author":[{"given":"Alexey V.","family":"Danilov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohad","family":"Bentur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sidransky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"67569","doi-asserted-by":"crossref","unstructured":"Flinn IW, Hillmen P, Montillo M. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood. 2018; 132(23):2446-2455.","DOI":"10.1182\/blood-2018-05-850461"},{"key":"67570","doi-asserted-by":"crossref","unstructured":"Brown JR, Hallek MJ, Pagel JM. Chemoimmunotherapy versus targeted treatment in chronic lymphocytic leukemia: when, how long, how much, and in which combination?. Am Soc Clin Oncol Educ Book. 2016; 35:e387-398.","DOI":"10.14694\/EDBK_159018"},{"key":"67571","unstructured":"COPIKTRA [package insert]. Secura Bio, Inc., Las Vegas NV USA. 2021."},{"key":"67572","unstructured":"FDA Briefing Document. Oncologic Drugs Advisory Committee Meeting. 2022."},{"key":"67573","doi-asserted-by":"crossref","unstructured":"Davids MS, Kuss BJ, Hillmen P. Efficacy and safety of duvelisib following disease progression on ofatumumab in patients with relapsed\/refractory CLL or SLL in the DUO crossover extension study. Clin Cancer Res. 2020; 26(9):2096-2103.","DOI":"10.1158\/1078-0432.CCR-19-3061"},{"key":"67574","doi-asserted-by":"crossref","unstructured":"Uno H, Claggett B, Tian L. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014; 32(22):2380-2385.","DOI":"10.1200\/JCO.2014.55.2208"},{"key":"67575","doi-asserted-by":"crossref","unstructured":"Pak K, Uno H, Kim DH. Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio. JAMA Oncol. 2017; 3(12):1692-1696.","DOI":"10.1001\/jamaoncol.2017.2797"},{"key":"67576","unstructured":"Briefing Document for the September 23,. US FDA Oncologic Drugs Advisory Committee Meeting. 2022."},{"key":"67577","unstructured":"Correction of Drug Information. Subject: Updated overall survival data for Copiktra (duvelisib) in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). 2022."},{"key":"67578","doi-asserted-by":"crossref","unstructured":"Mato AR, Davids MS, Sharman J. Recognizing unmet need in the era of targeted therapy for CLL\/SLL: \u201cWhat\u2019s past is prologue\u201d (Shakespeare). Clin Cancer Res. 2022; 28(4):603-608.","DOI":"10.1158\/1078-0432.CCR-21-1237"},{"key":"67579","doi-asserted-by":"crossref","unstructured":"Lampson BL, Brown JR. The evolving use of phosphatidylinositol 3-kinase inhibitors for the treatment of chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 2021; 35(4):807-826.","DOI":"10.1016\/j.hoc.2021.03.009"},{"key":"67580","doi-asserted-by":"crossref","unstructured":"Shouse G, Danilova OV, Danilov AV. Current status of phosphoinotiside-3 kinase inhibitors in blood cancers. Curr Opin Oncol. 2022; 34(5):540-545.","DOI":"10.1097\/CCO.0000000000000871"},{"key":"67581","unstructured":"A phase 3 study of ibrutinib (PCI-32765) versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia (RESONATE\u2122). ClinicalTrials.gov identifier: NCT01578707. 2024."},{"key":"67582","doi-asserted-by":"crossref","unstructured":"Brown JR, Byrd JC, Coutre SE. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed\/refractory chronic lymphocytic leukemia. Blood. 2014; 123(22):3390-3397.","DOI":"10.1182\/blood-2013-11-535047"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285043\/77109","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285043\/77584","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11624\/77109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:33Z","timestamp":1794045993000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":14,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285043","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}